Indena’s Custom Development & Manufacturing Organization (CDMO) services offer a full range of manufacturing capabilities for pharmaceutical ingredients. In a challenging CDMO framework, projects for customers can be very diversified…
Small is Powerful: A Globally Unique Capability for Nanoforming HPAPIs
By Dr. David Rowe – Head of Manufacturing and Antonio da Silva – Senior Director Business Operations, Nanoform In oncology and the wider pharmaceutical market, there is a surge in…
5 MINUTES WITH: Mikael Hagstroem, CEO, LabVantage Solutions
DCAT Value Chain Insights’ “5 Minutes With,” part of the DCAT Member Company Community section, features interviews with business and industry leaders on issues impacting the bio/pharmaceutical manufacturing value chain.…
By Jim Miller, Content Advisor/Consultant, DCAT. The CDMO sector experienced a strong 2021, but the question for 2022 is whether momentum continues as macroeconomic headwinds create uncertainty.
By Joel Ranck, Market Analyst, BioPlan Associates. What are key trends impacting biomanufacturing for 2022? COVID supply-chain challenges, unpredictable growth capacity, and China are major concerns.
